Vicuron Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference
25 Fevereiro 2005 - 9:30AM
PR Newswire (US)
Vicuron Pharmaceuticals to Present at the Wells Fargo Securities
Healthcare Conference KING OF PRUSSIA, Pa., Feb. 25
/PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq:
MICU; Nuovo Mercato) today announced that Dov A. Goldstein, M.D.,
Executive Vice President and CFO will present at the Wells Fargo
Securities Healthcare Conference at 1:30 p.m. Eastern Standard Time
on Tuesday, March 1, 2005 at the St. Regis Hotel in New York City.
To access the live audio broadcast or the subsequent archived
recording log on to http://www.vicuron.com/ and click on the
investor relations section. Please connect to the website several
minutes prior to the start of the webcast to ensure adequate time
for any software download that may be necessary. The live broadcast
will be archived for 30 days. About Vicuron Pharmaceuticals Vicuron
Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital
medicine for seriously ill patients. The company has two New Drug
Applications pending with the U.S. Food and Drug Administration for
its lead products, dalbavancin, a novel intravenous antibiotic for
the treatment of serious Gram-positive infections, and
anidulafungin, a novel antifungal agent. Vicuron's versatile
research engine integrates industry-leading expertise in functional
genomics, natural products discovery, mechanism-based drug design
and combinatorial and medicinal chemistry. These approaches are
yielding promising novel and next-generation compounds, many of
which are in the later stages of preclinical development. In
addition, the company has research and development collaborations
with leading pharmaceutical companies, such as Novartis and Pfizer.
Forward-Looking Statements The presentation contains
forward-looking statements that predict or describe future events
or trends. The matters described in these forward-looking
statements are subject to known and unknown risks, uncertainties
and other unpredictable factors, many of which are beyond Vicuron's
control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that
clinical trials and the results thereof might be delayed or
unsuccessful, that the timing of the filing of any new drug
application or any amendment to a new drug application might be
delayed, that clinical trials might indicate that a product
candidate is unsafe or ineffective, that the FDA might require
additional information to be submitted and additional actions to be
taken before it will make any decision, that any filed new drug
application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield
useful results, that the pipeline may not yield a new clinical
candidate or a commercial product, that a third party may not be
willing to license Vicuron's product candidates on terms acceptable
to it or at all, that competitors might develop superior
substitutes for Vicuron's products or market these competitive
products more effectively, that a sales force may not be developed
as contemplated and that one or more of Vicuron's product
candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission
contain a fuller description of these and many other risks to which
Vicuron is subject. Because of those risks, Vicuron's actual
results, performance or achievements may differ materially from the
results, performance or achievements contemplated by its
forward-looking statement. The information set forth in the
presentation represents management's current expectations and
intentions. Vicuron assumes no responsibility to issue updates to
the forward-looking matters discussed in the presentation.
DATASOURCE: Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein,
M.D. of Vicuron Pharmaceuticals Inc., +1-610-205-2312, ; or E.
Blair Schoeb of WeissComm Partners, +1-212-923-6737, ; or Aline
Schimmel of Burns McClellan Inc., +1-212-213-0006, ; both for
Vicuron Pharmaceuticals Inc. Web site: http://www.vicuron.com/
Copyright